Ronald Gentile, M.D.
To evaluate Retisert™ in the management of patients with diabetic macular edema.
The two year trial results demonstrated that 30% of eyes receiving standard of care (repeat laser treatment) had a worsening of their Diabetic Retinopathy compared with only 10% of eyes receiving a Retisert™ implant. This was statistically significant. Retisert™ also reduced retinal thickening involving the fovea (the centre most part of the macula responsible for sharp, central vision) and led to a statistically significant three line improvement in vision.
For more information: